Silence Therapeutics

siRNA
#Merck #Mergers and acquisitions #Silence Therapeutics #siRNA

Merck KGaA buys Silence Therapeutics for $1.3 billion

Merck KGaA is to acquire Silence Therapeutics, a biotechnology company developing precision engineered medicines using siRNA technology.   Merck has agreed to acquire Silence in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.  “We are pleased to have reached this agreement… Read More

#Business & Investment #News #Trending News

Human heart
#Cardiovascular disease #Heart disease #Phase II trial #RNA #Silence Therapeutics

Silence Therapeutics presents late-breaking Phase II data at AHA

Biotechnology company Silence Therapeutics has shared end-of-treatment data from its Phase II ALPACAR-360 study of short interfering RNA (siRNA) zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein levels. These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific… Read More

#News